GlassScriptPhysician profile
Anthony David Colvin
NPI 1831117324
$12,199.88
in general payments reported to CMS, 2019-2025
36 companies · $2,745 in 2025
The $2,745 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,401 · 2020: $829 · 2021: $1,282 · 2022: $1,484 · 2023: $2,087 · 2024: $2,371 · 2025: $2,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,160 · Education: $43.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,160.05 |
| Education | $43.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,217.51 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,774.85 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,755.02 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,211.26 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $644.60 | 2019-2024 | Linzess |
| Pfizer INC. | $530.28 | 2019-2025 | |
| Genzyme Corporation | $455.73 | 2022-2025 | |
| Qol Medical, LLC | $377.15 | 2019-2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $349.95 | 2023-2025 | Dupixent |
| Vivus LLC | $275.00 | 2022-2025 | Pancreaze, Qsymia |
| Alnylam Pharmaceuticals INC. | $251.10 | 2020-2022 | |
| Lilly USA, LLC | $229.44 | 2023-2025 | Omvoh |
| Daiichi Sankyo INC. | $225.70 | 2019-2024 | Injectafer |
| Aimmune Therapeutics, INC. | $221.39 | 2024-2025 | Zenpep |
| Celgene Corporation | $212.98 | 2022-2024 | Zeposia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $208.74 | 2021-2025 | |
| 3-D Matrix, INC. | $144.10 | 2024 | |
| Medtronic, INC. | $140.30 | 2022-2025 | Interstim |
| Madrigal Pharmaceuticals | $138.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $118.46 | 2020-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $107.98 | 2023-2025 | Voquezna |
| Amgen INC. | $107.18 | 2020-2025 | Uplizna, Amjevita |
| Ferring Pharmaceuticals INC. | $80.19 | 2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $73.70 | 2019-2024 | |
| Evoke Pharma, INC. | $64.45 | 2021-2024 | |
| Alfasigma USA, INC. | $51.11 | 2020 | |
| Celltrion USA INC. | $43.81 | 2024 | Zymfentra |
| Braintree Laboratories, INC. | $42.07 | 2022-2024 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $33.93 | 2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.56 | 2024 | Cyltezo |
| Ardelyx, INC. | $20.23 | 2025 | Ibsrela |
| Fresenius Kabi USA, LLC | $18.02 | 2024 | Idacio |
| Astrazeneca Pharmaceuticals LP | $13.34 | 2019 | |
| Covidien LP | $12.88 | 2019 | |
| Redhill Biopharma INC. | $12.79 | 2023 | Talicia |
| Nestle Healthcare Nutrition INC. | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Colvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.